The National Alliance of Advocates
for Buprenorphine Treatment

Local Resources

Important Info About the Physician Locator:

The list of DATA-2000 certified physicians originates from SAMHSA (Substance Abuse and Mental Health Services Administration) and is downloaded daily and posted on the NAABT site in its entirety. Unfortunately, we have no editing control and cannot maintain or update the list ourselves, thus many of the physicians listed are no longer accepting new patients, while others who are treating, wish not to be listed. NAABT created the patient matching system so patients could avoid some of the frustration of calling physicians unwilling to treat them, and also reach out for help 24/7- not just when physician offices are open.

Still Unable to find a physician by using the locator? Try the matching system

DATA-2000 Certified Physicians: Click here to register for this list or edit an existing listing

Inclusion on and use of the list is voluntary and at your own risk. NAABT, Inc. makes no claims or recommendations about the competency or current status of the physicians on the list. It is the responsibility of the patient to confirm the credentials and competency of any physician with their State Board of Health. Inclusion of a certified physician is not and does not imply any NAABT, Inc. referral, endorsement or recommendation, nor does the omission of any individual indicate any NAABT, Inc. disapproval. NAABT, Inc. shall not be liable to you or others for any decision made or action taken by you in reliance on the information obtained from this site.

---

 

Physician DATA-2000 Waiver Qualifications

The Drug Addiction Treatment Act of 2000 (DATA 2000) enables qualifying physicians to receive a waiver from the special registration requirements in the Controlled Substances Act for the provision of medication-assisted opioid therapy. This waiver allows qualifying physicians to practice medication-assisted opioid addiction therapy with Schedule III, IV, or V narcotic medications specifically approved by the Food and Drug Administration (FDA). On October 8, 2002 Subutex® (buprenorphine hydrochloride) and Suboxone® tablets (buprenorphine hydrochloride and naloxone hydrochloride) received FDA approval for the treatment of opioid addiction.

To receive a waiver to practice opioid addiction therapy with approved Schedule III, IV, or V narcotics a physician must notify the Center for Substance Abuse Treatment (CSAT, a component of the Substance Abuse and Mental Health Services Administration) of his or her intent to begin dispensing or prescribing this treatment. This Notification of Intent must be submitted to CSAT before the initial dispensing or prescribing of opioid therapy. The "waiver notification" section on this Site provides information on how to obtain and submit a Notification of Intent form. The Notification of Intent can be submitted on-line from this Web site, or via ground mail or fax.

The Notification of Intent must contain information on the physician's qualifying credentials (as defined below) and additional certifications including that the physician has the capacity to refer such addiction therapy patients for appropriate counseling and other non-pharmacologic therapies, and that the physician will not have more than 30 patients on such addiction therapy at any one time for the first year. (Note: The 30-patient limit is not affected by the number of a physician's practice locations. One year after the date on which the physician submitted the initial notification, the physician will be able to submit a second notification stating the need and intent to treat up to 100 patients.)

The Drug Enforcement Administration (DEA) assigns the physician a special identification number. DEA regulations require this ID number to be included on all buprenorphine prescriptions for opioid addiction therapy, along with the physician's regular DEA registration number.

To qualify for a waiver under DATA 2000 a licensed physician (MD or DO) must meet any one or more of the following criteria:

• The physician holds a subspecialty board certification in addiction psychiatry from the American Board of Medical Specialties.
• The physician holds an addiction certification from the American Society of Addiction Medicine.
• The physician holds a subspecialty board certification in addiction medicine from the American Osteopathic Association.
• The physician has, with respect to the treatment and management of opioid-addicted patients, completed not less than eight hours of training (through classroom situations, seminars at professional society meetings, electronic communications, or otherwise) that is provided by the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, the American Psychiatric Association, or any other organization that the Secretary determines is appropriate for purposes of this subclause.
• The physician has participated as an investigator in one or more clinical trials leading to the approval of a narcotic drug in schedule III, IV, or V for maintenance or detoxification treatment, as demonstrated by a statement submitted to the Secretary by the sponsor of such approved drug.
• The physician has such other training or experience as the State medical licensing board (of the State in which the physician will provide maintenance or detoxification treatment) considers to demonstrate the ability of the physician to treat and manage opioid-addicted patients.
• The physician has such other training or experience as the Secretary considers to demonstrate the ability of the physician to treat and manage opioid-addicted patients. Any criteria of the Secretary under this subclause shall be established by regulation. Any such criteria are effective only for 3 years after the date on which the criteria are promulgated, but may be extended for such additional discrete 3-year periods as the Secretary considers appropriate for purposes of this subclause. Such an extension of criteria may only be effectuated through a statement published in the Federal Register by the Secretary during the 30-day period preceding the end of the 3-year period involved

This page was last modified on : 10/29/2013